

1 **Genetic variants are identified to increase risk of COVID-19 related mortality from**

2 **UK Biobank data**

3 Jianchang Hu¹, Cai Li¹, Shiyang Wang, Ting Li, Heping Zhang*

4 Department of Biostatistics, Yale University

5 ¹Co-first Author

6 *Correspondence Author

7 Email: heping.zhang@yale.edu

8 300 George Street, Ste 523, New Haven, CT, 06511

9

10

11

12

13

14

15

16

17

18

19

20 **Abstract**

21 ***Background***

22 The severity of coronavirus disease 2019 (COVID-19) caused by the severe acute
23 respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly heterogenous. Studies have
24 reported that males and some ethnic groups are at increased risk of death from COVID-
25 19, which implies that individual risk of death might be influenced by host genetic
26 factors.

27 ***Methods***

28 In this project, we consider the mortality as the trait of interest and perform a genome-
29 wide association study (GWAS) of data for 1,778 infected cases (445 deaths, 25.03%)
30 distributed by the UK Biobank. Traditional GWAS failed to identify any genome-wide
31 significant genetic variants from this dataset. To enhance the power of GWAS and
32 account for possible multi-loci interactions, we adopt the concept of super-variant for the
33 detection of genetic factors. A discovery-validation procedure is used for verifying the
34 potential associations.

35 ***Results***

36 We find 8 super-variants that are consistently identified across multiple replications as
37 susceptibility loci for COVID-19 mortality. The identified risk factors on Chromosomes
38 2, 6, 7, 8, 10, 16, and 17 contain genetic variants and genes related to cilia dysfunctions
39 (*DNAH7* and *CLUAP1*), cardiovascular diseases (*DES* and *SPEG*), thromboembolic
40 disease (*STXBP5*), mitochondrial dysfunctions (*TOMM7*), and innate immune system

41 (*WSBI*). It is noteworthy that *DNAH7* has been reported recently as the most
42 downregulated gene after infecting human bronchial epithelial cells with SARS-CoV2.

43 ***Conclusions***

44 Eight genetic variants are identified to significantly increase risk of COVID-19 mortality
45 among the patients with white British ancestry. These findings may provide timely
46 evidence and clues for better understanding the molecular pathogenesis of COVID-19
47 and genetic basis of heterogeneous susceptibility, with potential impact on new
48 therapeutic options.

49 ***Keywords***

50 COVID-19, GWAS, Host genetic factors, Mortality, SARS-CoV2, UK Biobank

51

52

53

54

55

56

57

58

59

60 **Introduction**

61 Coronavirus disease 2019 (COVID-19) is a highly infectious disease caused by the severe
62 acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pneumonia was first
63 reported in December 2019 in Wuhan, Hubei Province, China, followed by an outbreak
64 across the country [1, 2]. As of September 8th, 2020, the pandemic of COVID-19 has
65 rapidly spread worldwide and caused over 27 million infected cases and 891,000 deaths
66 (3.3%) according to JHU COVID-19 dashboard [3]. Currently, the effective therapeutic
67 measures available to counteract the SARS-CoV-2 are limited. While studies have been
68 dedicated to investigating the clinical features, epidemiological characteristics of
69 COVID-19 [4-11], and genomic characterization of SARS-CoV-2 [12], few are through
70 the lens of statistical genetics and the host genetic factors contributing to COVID-19
71 remain largely enigmatic [13, 14]. Moreover, the severity of COVID-19 and course of the
72 infection is highly heterogenous. The majority of COVID-19 cases only have mild or no
73 symptoms, while some of the patients develop serious health outcomes. A UK cross-
74 sectional survey of 20,133 patients who were hospitalized with COVID-19 showed that
75 patients with diabetes, cardiovascular diseases, hypertension, or chronic respiratory
76 diseases were at higher risk of death [15]. More importantly, evidence has shown that
77 males and some ethnic groups have increased risk of death from COVID-19 [16-20].
78 These observations suggest that there might be host genetic determinants which
79 predispose the subgroup of patients to more severe COVID-19 outcomes. Undoubtedly,
80 there is an urgent need for understanding host genetic basis of heterogeneous
81 susceptibility to COVID-19 and uncovering genetic risk factors. Current studies mainly
82 focus on investigating associations between host genetic factors and infection or

83 respiratory failure [13, 14]. Obviously, infection may only be partially explained by
84 genetic factors since exposure to the virus could be more important. Here, we consider
85 the mortality as the trait of interest for our analysis.

86 As of early August 2020, UK Biobank [21, 22] has released the testing results of
87 COVID-19 for 12,428 participants, including 1,778 (14.31%) infected cases with 445
88 deaths related to COVID-19. This dataset accompanied by already available health care
89 data, genetic data and death data offers a unique resource and timely opportunity for
90 learning the host genetic determinants of COVID-19 susceptibility, severity, and
91 mortality.

92 In this project, we perform a genome-wide association study (GWAS) exploiting the
93 concept of super-variables in statistical genetics to identify potential risk loci contributing
94 to the COVID-19 mortality. A super-variant is a combination of alleles in multiple loci in
95 analogue to a gene. However, in contrast to a gene that refers to a physically connected
96 region of a chromosome, the loci contributing to a super-variant is not restricted by its
97 spatial location in the genome [23-25]. The rationale behind our analysis is two-fold:
98 First, COVID-19 infections require environmental exposure and the genetic contribution
99 may be limited relative to the environmental exposure, and the mortality may have a
100 stronger genetic effect. Second, COVID-19 is a complex syndrome, which may reflect
101 interacting genomic factors, and our analysis with super-variants enables leveraging gene
102 interactions beyond the additive effects.

103

104 **Methods**

105 *Sample processing and genotype quality control*

106 We analyze the COVID-19 data released by UK Biobank (Category ID: 100091) [22] on
107 August 3rd, 2020, which include in total 1,778 of COVID-19 infected cases. Here, we
108 consider an infected case as a sample with any positive PCR test result or a death with
109 virus found. Among infected cases, 445 of them were reported death caused directly or
110 indirectly by COVID-19 and the remainder of 1333 patients are survivors. In our
111 analysis, to limit the potential effect of population structure, we focus on samples from
112 white British ancestry. After standard sample quality controls, there remain 1096 of
113 COVID-19 infected participants, of which 292 were deaths (26.64%) and 804 were
114 survivors. Their imputed genotype data (Field ID: 22801-22822) and clinical variables
115 including gender and age (Field ID: 31, 34) are all accessible from UK Biobank [21].

116 Our analysis makes use of imputed single-nucleotide polymorphism (SNP) datasets from
117 UK Biobank. SNPs with duplicated names and positions are excluded. After standard
118 genotyping quality control, where variants with low call rate (missing probability ≥ 0.05)
119 and disrupted Hardy-Weinberg equilibrium ($p\text{-value} < 1 \times 10^{-6}$) are removed, we retain in
120 total 18,617,478 SNPs. We divide the whole SNP dataset into 2734 non-overlapping
121 local sets according to the physical position so that each set consists of SNPs within a
122 segment of physical length 1 Mb.

123 *Statistical analysis*

124 We consider the concept of super-variant for GWAS. A super-variant is a combination of
125 alleles in multiple loci, but unlike a gene that refers to a physically connected region of
126 chromosome, the loci contributing to a super-variant can be anywhere in the genome [24,

127 25]. The super-variant is suggested to be powerful and stable in association studies as it
128 aggregates the strength of individual signals. In addition, it accounts for potential
129 complex interactions between different genes even when they are located remotely. To
130 identify significant super-variants, a local ranking and aggregation method is adopted.
131 Chromosomes are divided into local SNP sets. Within each set, random forest technique
132 is utilized to obtain the so-called depth importance measure of each SNP which leads to a
133 ranking of SNPs in terms of their importance. Top SNPs within each local set are then
134 aggregated into a super-variant. In addition, two modes of transmission, dominant and
135 recessive modes are both considered for the super-variant identification. We refer the
136 readers to [25] for details.

137 Our analysis considers the following discovery-validation procedure. The complete
138 dataset is randomly divided into two sets, one for discovery and the other for verification.
139 Each set consists of 146 deaths and 402 survivors. We apply the aforementioned ranking
140 and aggregation method for super-variant identification on the discovery dataset. After
141 the discovery of the super-variants, we then investigate their associations with the death
142 outcomes of COVID-19 through logistic regression in the verification and complete
143 datasets. Age and gender are considered in the regression analyses as confounders to
144 remove potential bias. We use 1.83×10^{-5} (i.e., $0.05/2734$) as the threshold for super-
145 variant-level association on the discovery dataset since 2,734 SNP sets are considered. A
146 super-variant is verified if its logistic regression coefficient achieves the level of 0.05
147 significance on the verification dataset and super-variant-level significance on the
148 complete dataset.

149 To ascertain the stability of the associations, we repeat the above procedure for 10 times,
150 and retain the verified super-variants and their contributing SNPs. Finally, for super-
151 variants that are consistently verified across multiple runs, we conduct Cox regressions
152 with adjustment for age and gender in the complete dataset to further validate their
153 associations.

154

155 **Results**

156 We find 216 different verified super-variants across 10 repetitions of the discovery-
157 validation procedure. More importantly, there are two super-variants, chr6_148 and
158 chr7_23, identified in 4 out of 10 repetitions. In addition, there are 6 super-variants,
159 chr2_197, chr2_221, chr8_99, chr10_57, chr16_4 and chr17_26 identified in 3 out of 10
160 repetitions. According to the binomial distribution, the probability of a super-variant
161 being verified in 4 (3) out of 10 repetitions by chance is at most 0.00096 (0.0105) if p-
162 value in the verification dataset is assumed to be uniformly distributed.

163 In terms of the SNPs contributing to these 8 super-variants, there exist SNPs selected
164 multiple times across different repetitions. Specifically, for chr6_148, SNP rs117928001
165 is a contributing SNP in all 4 times when this super-variant is verified, and there are other
166 94 contributing SNPs selected 3 times. Similarly, for chr7_23, SNP rs1322746 is a
167 contributing SNP in 3 repetitions when this super-variant is verified, and other 4 SNPs
168 are selected 2 times. For super-variant chr2_197 which is identified in 3 out of 10
169 repetitions, SNPs rs34011564 and rs71040457 are both contributing SNPs in all 3 times.
170 For chr8_99, SNPs rs4735444 and rs531453964 are contributing SNPs of verified super-

171 variants in all 3 repetitions. SNPs rs117217714, rs2176724, rs9804218 and rs2301762 are
172 contributing SNPs for chr17_26, chr2_197, chr10_57 and chr16_4 in all 3 repetitions
173 when these super-variants are verified, respectively. We calculate minor allele frequency
174 (MAF), odds ratio (OR), and p-value for the contributing SNPs of the 8 super-variants
175 based on the complete dataset. See Table S1 in Additional file 1 for the details of all
176 contributing SNPs which are selected in at least 2 repetitions.

177 We use SNPs which are selected in at least 2 repetitions to representatively form 8 super-
178 variants according to the same mode of transmission (dominant/recessive) when they are
179 discovered. Table 1 gives their effects estimated from univariate logistic regression and
180 Cox regression with adjustment for sex and age in the complete dataset. For the logistic
181 regression, all of them achieve super-variant-level significance (i.e., p-value $< 1.83 \times 10^{-5}$).
182 The strongest signal in terms of p-value is given by chr7_23 (p-value = 9.5×10^{-9}), and the
183 largest odds ratio appears at chr17_26 (OR = 4.237). For the Cox regression, the largest
184 individual hazards ratio (HR) appears at chr17_26 (HR = 2.956) as well, and the smallest
185 individual p-value is given by chr2_221 (p-value = 5.2×10^{-9}). Table 2 lists the details of
186 representative contributing SNPs with high selection frequency and important gene
187 mapping results of the 8 super-variants. Figure 1 shows that the survival probabilities of
188 the patients with identified super-variants remarkably drop during the first 20 days since
189 testing, suggesting of risk genotypes. Figure 2 presents the survival probabilities stratified
190 by the number of super-variants. The HR of super-variants is 1.778 with 95% CI being
191 [1.593, 1.985], and the associated p-value is 1.1×10^{-24} , while the p-values of sex and age
192 are 1.2×10^{-2} (HR = 1.489, male) and 2.9×10^{-18} (HR = 1.107), respectively. The survival

193 probability of patients with more than 3 super-variants dramatically decreases to around
194 0.6 during the first three weeks.

195 In addition, we use a chi-square test for independence to investigate whether there are
196 any gender differences among distribution of these 8 super-variants as well as differences
197 among distribution of contributing SNPs. For super-variants, chr2_197 has p-value
198 0.0579 when all samples are considered. The frequency of presenting this super-variant
199 among males and females is 18.09% and 22.93%, respectively. For contributing SNPs,
200 rs4346407 on chromosome 2 has p-value 0.050 when all samples are considered, and SNP
201 10:56525802_CT_C has p-value 0.0078 when only death cases are considered. The
202 distributions of these two SNPs are given in Table 3.

203

204 **Discussion**

205 As the COVID-19 pandemic creates a global crisis of overwhelming morbidity and
206 mortality, it is urgent and imperative to provide insights into how host genetic factors link
207 to clinical outcomes. With the timely release of UK Biobank COVID-19 dataset, we
208 perform a GWAS study for detecting genetic risk factors for COVID-19 mortality.
209 However, due to the limited sample size, the traditional single SNP GWAS has low
210 power in signal detection which is evidenced by the Manhattan plot shown in Figure 3.
211 This traditional association analysis is also conducted on the same samples with white
212 British ancestry and controlled for gender and age. As demonstrated, the traditional single
213 SNP analysis method is unable to detect any genome-wide significant association with

214 commonly used threshold 5×10^{-8} , which motivates us to consider the concept of super-
215 variant for GWAS study.

216 Although the identified super-variants are similarly distributed in males and females, the
217 results presented in Table 3 suggest that males tend to present more minor alleles for two
218 contributing SNPs rs4346407 and 10:56525802_CT_C which potentially increase their
219 risk of COVID-19 mortality. Such a phenomenon of higher risk for males has been
220 reported in recent studies [17, 18, 26, 27].

221 The identified super-variants are mapped to annotated genes. The most interesting signal
222 appears on chromosome 2 in the super-variant chr2_197. Within this super-variant, SNPs
223 rs200008298, rs183712207, and rs191631470 are located in gene *DNAH7*. This gene
224 encodes dynein axonemal heavy chain 7, which is a component of the inner dynein arm
225 of ciliary axonemes. Gene Ontology (GO) annotations related to this gene include cilia
226 movement and microtubule motor activity. A recently published paper showed that gene
227 *DNAH7* is the most downregulated gene after infecting human bronchial epithelial cells
228 with SARS-CoV2 [28]. The authors of that study speculated that the down-regulation of
229 gene *DNAH7* causes the reduction of function of respiratory cilia. Our results suggest that
230 COVID-19 patients with variations in gene *DNAH7* have higher risk for dying from
231 COVID-19. We hypothesize that the disruption of *DNAH7* gene function may result in
232 ciliary dysmotility and weakened mucociliary clearance capability, which leads to severe
233 respiratory failure, a likely cause of COVID-19 death [29]. In addition, within the super-
234 variant chr2_197, SNPs rs4578880 and rs113892140 are located in gene *SLC39A10*,
235 which encodes a zinc transporter. This gene plays an important role in mediating immune
236 cell homeostasis. It has been reported to facilitate antiapoptotic signaling during early B-

237 cell development [30], modulate B-cell receptor signal strength [31], and control
238 macrophage survival [32].

239 Signal at super-variant chr16_4 is also related to cilia. This super-variant consists of a
240 single SNP rs2301762, which is located in gene *CLUAPI*. This gene encodes clusterin-
241 associated protein 1. It is an evolutionarily conserved protein required for ciliogenesis
242 [33], and its GO annotations include intraciliary transport involved in cilium assembly.
243 Our findings evidence the importance of respiratory cilia functioning properly in
244 COVID-19 patients, which may be an important site in host-pathogen interaction during
245 SARS-CoV2 infection of airways [34] as well as a potential therapeutic target [35].

246 It is noteworthy that both super-variants chr2_197 and chr16_4 are related to cilia, which
247 plays a crucial role in SARS-CoV-2 infection. Studies have reported that the angiotensin-
248 converting enzyme II (ACE2) receptors on oral and nasal epithelium cells are the main
249 portal for SARS-CoV-2 infection and transmission [36, 37]. Viral proliferation in the
250 airway disrupts the structure and function of ciliated epithelium, causes ciliary dyskinesia
251 and leads to lower respiratory tract infection [38]. Moreover, it has been reported that
252 dysfunctions in olfactory cilia lead to loss of smell (anosmia), a COVID-19 associated
253 symptom, and coronavirus hijacks the ciliated cells and causes deciliation in the human
254 nasal epithelium [39].

255 Chr2_221 consists of 3 SNPs. SNP rs71040457 is located in the downstream of gene
256 *DES* (distance = 3322 bp) and the upstream of gene *SPEG* (distance = 4917 bp). Gene
257 *DES* encodes a muscle-specific class III intermediate filament. Its GO annotations
258 include protein binding, structural constituent of cytoskeleton, and regulation of heart
259 contraction. Gene *SPEG* encodes striated muscle enriched protein kinase, whose

260 functions are related to protein kinase activity and muscle cell differentiation. Mutations
261 in both gene *DES* and *SPEG* are reported to be associated with cardiomyopathy [40-42].
262 Several studies have reported cardiomyopathy in COVID-19 patients [43, 44], and acute
263 myocardial damage caused by SARS-CoV-2 greatly increases the difficulty and
264 complexity of patient treatment [45].

265 Chr7_23 is composed by five intergenic variant SNPs. Among them, SNP rs55986907 is
266 an expression quantitative trait loci (eQTL) of gene *TOMM7* in multiple tissues,
267 including whole blood, lung, adipose, thyroid, skin, nerve, and esophagus based on the
268 Genotype-Tissue Expression (GTEx) database. The gene product of *TOMM7* is a subunit
269 of the translocase of the outer mitochondrial membrane, and plays a role in regulating the
270 assembly and stability of the translocase complex [46]. A study discussed that intra and
271 extracellular mitochondrial function can be impacted by SARS-CoV-2, which may be
272 related to the hyper-inflammatory state termed as the “cytokine storm” found in COVID-
273 19 patients, with contributions to the progression and severity of the disease [47]. Super
274 variant chr6_148 contains 101 SNPs. Eighty-nine of them are located in gene
275 *STXBP5* and six of them are located in gene *STXBP5-AS1*. On the one hand, gene
276 *STXBP5* encodes a syntaxin 1 binding protein. Its GO annotations include
277 neurotransmitter release and regulation of synaptic vesicle exocytosis. Genome-wide
278 association studies have found the association between *STXBP5* and Von Willebrand
279 factor (VWF) plasma level in humans [48, 49], which is a predictor for the risk of
280 myocardial infarction and thrombosis. A study showed that gene *STXBP5* inhibits
281 endothelial exocytosis and promotes platelet secretion, and the variation
282 within *STXBP5* is a genetic risk for venous thromboembolic disease [50]. COVID-19

283 leads to excessive inflammation, platelet activation, endothelial dysfunction, and stasis,
284 which may predispose patients to venous and arterial thrombotic disease [51]. On the
285 other hand, studies have revealed that *STXBP5-AS1* encodes a long noncoding RNA,
286 which inhibits cell proliferation, migration, and invasion via preventing the
287 phosphatidylinositol 3 kinase/protein kinase B (PI3K/AKT) signaling pathway against
288 *STXBP5* expression in non-small-cell lung carcinoma and gastric cancer cells [52, 53].
289 Our results suggest that the variations within *STXBP5/STXBP5-AS1* and the interaction
290 between them may result in increased risk of death among COVID-19 patients through
291 the mechanism related to endothelial exocytosis.

292 Chr17_26 is composed by three intergenic variant SNPs. Among them, SNP rs60811869
293 is an eQTL of gene *WSBI* in Artery-Tibial tissue based on the GTEx database. Gene
294 *WSBI* encodes a member of the WD-protein subfamily, which is highly expressed in
295 spleen and lung [54]. Its related pathways include innate immune system and Class I
296 MHC mediated antigen processing and presentation. This gene has been reported to
297 function as a Lnterleukin-21(IL-21) receptor binding molecule, which enhances the
298 maturation of IL-21 receptor [55]. Variations in this gene may result in disrupted
299 functions of immune system and lead to higher death rate among COVID-19 patients.

300 Super-variant chr10_57 contains 11 SNPs and all of them are located in gene *PCDH15*.
301 This gene is a member of the cadherin superfamily, which encodes a Calcium-dependent
302 cell-adhesion protein. Gene *PCDH15* is essential for maintenance of normal retinal and
303 cochlear function.

304 Super-variant chr8_99 is composed by 7 SNPs. All the SNPs are located in gene *CPQ*,
305 which encodes carboxypeptidase Q. GO annotations of this gene include protein
306 homodimerization activity and carboxypeptidase activity.

307 Although the roles of genes *PCDH15* and *CPQ* in viral infection remain largely unclear,
308 our results warrant future investigation to learn the relationship between genetic
309 variations and the severe COVID-19 outcomes.

310 Our study is restricted by the limited sample size. We anticipate a continuous
311 accumulation of data in the following months and plan to iterate our analysis whenever
312 more data become available. Furthermore, we currently focus on the population with
313 white British ancestry of UK Biobank in the analysis, validating the identified risk factors
314 in independent populations from other resources or ethnic groups worth further
315 investigation.

316

317 **Conclusions**

318 We identify 8 potential genetic risk loci for the mortality of COVID-19. These findings
319 may provide timely evidence and clues for better understanding the molecular
320 pathogenesis of COVID-19 and genetic basis of heterogeneous susceptibility, with
321 potential impact on new therapeutic options.

322

323 **Declarations**

324 *Ethics approval and consent to participate*

325 Ethical approval and participant consent were collected by UK Biobank at the time
326 participants enrolled. This paper is an analysis of anonymized data provided by UK
327 Biobank. According to Yale IRB, analysis of anonymized data does not constitute Human
328 Subjects Research.

329

330 *Consent for publication*

331 Not applicable.

332

333 *Availability of data and material*

334 The data used in the study are available with the permission of the UK Biobank
335 (<https://www.ukbiobank.ac.uk>).

336

337 *Competing interests*

338 The authors declare that they have no competing interests.

339

340 *Funding*

341 Partially funded by U.S. National Institutes of Health R01HG010171 and
342 R01MH116527.

343

344 *Authors' contributions*

345 JH, CL, and HZ designed the study. JH, CL, SW, and TL performed the experiments and
346 analyzed the data. All authors made critical input to the manuscript.

347

348 *Acknowledgements*

349 Zhang's research is supported in part by U.S. National Institutes of Health
350 (R01HG010171 and R01MH116527). This research has been conducted using the UK
351 Biobank Resource under Application Number 42009. We thank the Yale Center for
352 Research Computing for guidance and use of the research computing infrastructure.

353

354 Reference

- 355 1. Zhu, N., et al., *A novel coronavirus from patients with pneumonia in China, 2019*. New
356 England Journal of Medicine, 2020.
- 357 2. Huang, C., et al., *Clinical features of patients infected with 2019 novel coronavirus in*
358 *Wuhan, China*. The Lancet, 2020. **395**(10223): p. 497-506.
- 359 3. Dong, E., H. Du, and L. Gardner, *An interactive web-based dashboard to track COVID-19*
360 *in real time*. The Lancet infectious diseases, 2020. **20**(5): p. 533-534.
- 361 4. Chen, H., et al., *Clinical characteristics and intrauterine vertical transmission potential of*
362 *COVID-19 infection in nine pregnant women: a retrospective review of medical records*.
363 The Lancet, 2020. **395**(10226): p. 809-815.
- 364 5. Chen, N., et al., *Epidemiological and clinical characteristics of 99 cases of 2019 novel*
365 *coronavirus pneumonia in Wuhan, China: a descriptive study*. The Lancet, 2020.
366 **395**(10223): p. 507-513.
- 367 6. Guan, W.-j., et al., *Clinical characteristics of coronavirus disease 2019 in China*. New
368 England Journal of Medicine, 2020.
- 369 7. Wang, D., et al., *Clinical characteristics of 138 hospitalized patients with 2019 novel*
370 *coronavirus–infected pneumonia in Wuhan, China*. Jama, 2020. **323**(11): p. 1061-1069.
- 371 8. Xu, X.-W., et al., *Clinical findings in a group of patients infected with the 2019 novel*
372 *coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series*. bmj, 2020.
373 **368**.
- 374 9. Pan, A., et al., *Association of public health interventions with the epidemiology of the*
375 *COVID-19 outbreak in Wuhan, China*. JAMA, 2020.
- 376 10. Li, Q., et al., *Early transmission dynamics in Wuhan, China, of novel coronavirus–infected*
377 *pneumonia*. New England Journal of Medicine, 2020.
- 378 11. Williamson, E.J., et al., *Factors associated with COVID-19-related death using*
379 *OpenSAFELY*. Nature, 2020. **584**(7821): p. 430-436.
- 380 12. Lu, R., et al., *Genomic characterisation and epidemiology of 2019 novel coronavirus:*
381 *implications for virus origins and receptor binding*. The Lancet, 2020. **395**(10224): p. 565-
382 574.
- 383 13. Ellinghaus, D., et al., *Genomewide association study of severe Covid-19 with respiratory*
384 *failure*. New England Journal of Medicine, 2020.
- 385 14. Initiative, T.H.G., *The COVID-19 Host Genetics Initiative, a global initiative to elucidate*
386 *the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus*
387 *pandemic*. European Journal of Human Genetics, 2020: p. 1.
- 388 15. Docherty, A.B., et al., *Features of 20 133 UK patients in hospital with covid-19 using the*
389 *ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study*.
390 bmj, 2020. **369**.
- 391 16. Stoian, A.P., et al., *Gender differences in the battle against COVID - 19: impact of*
392 *genetics, comorbidities, inflammation and lifestyle on differences in outcomes*.
393 International journal of clinical practice, 2020: p. e13666.
- 394 17. Sharma, G., A.S. Volgman, and E.D. Michos, *Sex differences in mortality from COVID-19*
395 *pandemic: are men vulnerable and women protected?* JACC: Case Reports, 2020. **2**(9): p.
396 1407-1410.
- 397 18. Jin, J.-M., et al., *Gender differences in patients with COVID-19: Focus on severity and*
398 *mortality*. Frontiers in Public Health, 2020. **8**: p. 152.

- 399 19. Pareek, M., et al., *Ethnicity and COVID-19: an urgent public health research priority*. The
400 Lancet, 2020. **395**(10234): p. 1421-1422.
- 401 20. Aldridge, R.W., et al., *Black, Asian and Minority Ethnic groups in England are at*
402 *increased risk of death from COVID-19: indirect standardisation of NHS mortality data*.
403 Wellcome Open Research, 2020. **5**(88): p. 88.
- 404 21. Sudlow, C., et al., *UK biobank: an open access resource for identifying the causes of a*
405 *wide range of complex diseases of middle and old age*. PLoS medicine, 2015. **12**(3).
- 406 22. Armstrong, J., et al., *Dynamic linkage of COVID-19 test results between public health*
407 *england's second generation surveillance system and UK Biobank*. [Google Scholar].
408 Microb Genomics, 2020.
- 409 23. Song, C. and H. Zhang, *TARV: Tree - based Analysis of Rare Variants Identifying Risk*
410 *Modifying Variants in CTNNA2 and CNTNAP2 for Alcohol Addiction*. Genetic
411 epidemiology, 2014. **38**(6): p. 552-559.
- 412 24. Madsen, B.E. and S.R. Browning, *A groupwise association test for rare mutations using a*
413 *weighted sum statistic*. PLoS genetics, 2009. **5**(2).
- 414 25. Hu, J., et al., *Supervariants identification for breast cancer*. Genetic Epidemiology, 2020.
- 415 26. Scully, E.P., et al., *Considering how biological sex impacts immune responses and COVID-*
416 *19 outcomes*. Nature Reviews Immunology, 2020: p. 1-6.
- 417 27. Takahashi, T., et al., *Sex differences in immune responses that underlie COVID-19 disease*
418 *outcomes*. Nature, 2020: p. 1-9.
- 419 28. Nunnari, G., et al., *Network perturbation analysis in human bronchial epithelial cells*
420 *following SARS-CoV2 infection*. Experimental Cell Research, 2020: p. 112204.
- 421 29. Li, X. and X. Ma, *Acute respiratory failure in COVID-19: is it "typical" ARDS?* Critical Care,
422 2020. **24**: p. 1-5.
- 423 30. Miyai, T., et al., *Zinc transporter SLC39A10/ZIP10 facilitates antiapoptotic signaling*
424 *during early B-cell development*. Proceedings of the National Academy of Sciences,
425 2014. **111**(32): p. 11780-11785.
- 426 31. Hojyo, S., et al., *Zinc transporter SLC39A10/ZIP10 controls humoral immunity by*
427 *modulating B-cell receptor signal strength*. Proceedings of the National Academy of
428 Sciences, 2014. **111**(32): p. 11786-11791.
- 429 32. Gao, H., et al., *Metal transporter Slc39a10 regulates susceptibility to inflammatory*
430 *stimuli by controlling macrophage survival*. Proceedings of the National Academy of
431 Sciences, 2017. **114**(49): p. 12940-12945.
- 432 33. Pasek, R.C., et al., *Mammalian Clusterin associated protein 1 is an evolutionarily*
433 *conserved protein required for ciliogenesis*. Cilia, 2012. **1**(1): p. 20.
- 434 34. Kuek, L.E. and R.J. Lee, *First contact: The role of respiratory cilia in host-pathogen*
435 *interactions in the airways*. American Journal of Physiology-Lung Cellular and Molecular
436 Physiology, 2020.
- 437 35. Joskova, M., J. Mokry, and S. Franova, *Respiratory cilia as a therapeutic target of*
438 *phosphodiesterase inhibitors*. Frontiers in Pharmacology, 2020. **11**.
- 439 36. Xu, H., et al., *High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of*
440 *oral mucosa*. International journal of oral science, 2020. **12**(1): p. 1-5.
- 441 37. Sungnak, W., et al., *SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells*
442 *together with innate immune genes*. Nature medicine, 2020. **26**(5): p. 681-687.
- 443 38. Curran, C.S., D.R. Rivera, and J.B. Kopp, *COVID-19 Usurps Host Regulatory Networks*.
444 Frontiers in Pharmacology, 2020. **11**: p. 1278.
- 445 39. Li, W., M. Li, and G. Ou, *COVID - 19, cilia, and smell*. The FEBS Journal, 2020.

- 446 40. Brodehl, A., A. Gaertner-Rommel, and H. Milting, *Molecular insights into*
447 *cardiomyopathies associated with desmin (DES) mutations*. *Biophysical reviews*, 2018.
448 **10**(4): p. 983-1006.
- 449 41. Liu, X., et al., *Disruption of striated preferentially expressed gene locus leads to dilated*
450 *cardiomyopathy in mice*. *Circulation*, 2009. **119**(2): p. 261.
- 451 42. Agrawal, P.B., et al., *SPEG interacts with myotubularin, and its deficiency causes*
452 *centronuclear myopathy with dilated cardiomyopathy*. *The American Journal of Human*
453 *Genetics*, 2014. **95**(2): p. 218-226.
- 454 43. Arentz, M., et al., *Characteristics and outcomes of 21 critically ill patients with COVID-19*
455 *in Washington State*. *Jama*, 2020. **323**(16): p. 1612-1614.
- 456 44. Guo, T., et al., *Cardiovascular implications of fatal outcomes of patients with coronavirus*
457 *disease 2019 (COVID-19)*. *JAMA cardiology*, 2020.
- 458 45. Zheng, Y.-Y., et al., *COVID-19 and the cardiovascular system*. *Nature Reviews Cardiology*,
459 2020. **17**(5): p. 259-260.
- 460 46. Hönlinger, A., et al., *Tom7 modulates the dynamics of the mitochondrial outer*
461 *membrane translocase and plays a pathway - related role in protein import*. *The EMBO*
462 *journal*, 1996. **15**(9): p. 2125-2137.
- 463 47. Saleh, J., et al., *Mitochondria and Microbiota dysfunction in COVID-19 pathogenesis*.
464 *Mitochondrion*, 2020.
- 465 48. Smith, N.L., et al., *Novel associations of multiple genetic loci with plasma levels of factor*
466 *VII, factor VIII, and von Willebrand factor: The CHARGE Consortium*. *Circulation*, 2010.
467 **121**(12): p. 1382.
- 468 49. Antoni, G., et al., *Combined analysis of three genome-wide association studies on vWF*
469 *and FVIII plasma levels*. *BMC medical genetics*, 2011. **12**(1): p. 102.
- 470 50. Zhu, Q., et al., *Syntaxin-binding protein STXBP5 inhibits endothelial exocytosis and*
471 *promotes platelet secretion*. *The Journal of clinical investigation*, 2014. **124**(10): p. 4503-
472 4516.
- 473 51. Bikdeli, B., et al., *COVID-19 and Thrombotic or Thromboembolic Disease: Implications for*
474 *Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review*.
475 *Journal of the American College of Cardiology*, 2020. **75**(23): p. 2950-2973.
- 476 52. Huang, J., et al., *Long noncoding RNA STXBP5 - AS1 inhibits cell proliferation, migration,*
477 *and invasion via preventing the PI3K/AKT against STXBP5 expression in non - small - cell*
478 *lung carcinoma*. *Journal of cellular biochemistry*, 2019. **120**(5): p. 7489-7498.
- 479 53. Cen, D., et al., *Long noncoding RNA STXBP5-AS1 inhibits cell proliferation, migration, and*
480 *invasion through inhibiting the PI3K/AKT signaling pathway in gastric cancer cells*.
481 *OncoTargets and therapy*, 2019. **12**: p. 1929.
- 482 54. Fagerberg, L., et al., *Analysis of the human tissue-specific expression by genome-wide*
483 *integration of transcriptomics and antibody-based proteomics*. *Molecular & Cellular*
484 *Proteomics*, 2014. **13**(2): p. 397-406.
- 485 55. Nara, H., et al., *WSB-1, a novel IL-21 receptor binding molecule, enhances the*
486 *maturation of IL-21 receptor*. *Cellular Immunology*, 2011. **269**(1): p. 54-59.

487

488

489 **Figures and Tables**

490 Figure 1: Survival curves of 8 identified super-variants in the complete dataset. The x-
491 axis represents days since testing, and the y-axis represents the survival probability.

492

493 Figure 2: Survival curves stratified by the number of super-variants in the complete
494 dataset. The x-axis represents days since testing, and the y-axis represents the survival
495 probability.

496

497 Figure 3: Manhattan plot of traditional single SNP association analysis based on samples
498 with white British ancestry only and controlled for gender and age. The red horizontal
499 line corresponds to the commonly adopted genome-wide significant level at 5×10^{-8} , and
500 the blue horizontal line gives to the suggestive significant level at 1×10^{-5} . Top SNPs
501 above the suggestive line in each chromosome are annotated.

502

503 Table 1: Marginal effects of 8 super-variants in the complete dataset.

504

505 Table 2: SNPs with high selection frequency and important gene mapping results in 8
506 super-variants.

507

508 Table 3: Allelic distribution of contributing SNPs.

509

Table 1 | Marginal effects of 8 super-variants in the complete dataset.

Dominant	Gene	OR	95% CI of OR	p value	HR	95% CI of HR	p value
chr6_148	<i>STXBP5/STXBP5-AS1</i>	2.909	[1.938, 4.365]	1.4x10 ⁻⁷	2.048	[1.435, 2.921]	7.7x10 ⁻⁵
chr8_99	<i>CPQ</i>	1.923	[1.419, 2.605]	1.6x10 ⁻⁵	1.502	[1.119, 2.015]	6.7x10 ⁻³
chr16_4	<i>CLUAP1</i>	2.725	[1.744, 4.259]	7.0x10 ⁻⁶	2.123	[1.433, 3.143]	1.7x10 ⁻⁴
chr17_26	<i>WSB1</i>	4.237	[2.472, 7.263]	8.4x10 ⁻⁸	2.956	[1.949, 4.482]	3.4x10 ⁻⁷
Recessive	Gene	OR	95% CI of OR	p value	HR	95% CI of HR	p value
ch2_197	<i>DNAH7/SLC39A10</i>	2.553	[1.801, 3.616]	7.3x10 ⁻⁸	1.625	[1.170, 2.257]	3.8x10 ⁻³
chr2_221	<i>DES/SPEG</i>	2.739	[1.893, 3.963]	4.9x10 ⁻⁸	2.614	[1.894, 3.609]	5.2x10 ⁻⁹
chr7_23	<i>TOMM7</i>	2.411	[1.774, 3.276]	9.5x10 ⁻⁹	1.943	[1.451, 2.603]	8.1x10 ⁻⁶
chr10_57	<i>PCDH15</i>	2.521	[1.736, 3.662]	7.1x10 ⁻⁷	1.813	[1.283, 2.561]	7.4x10 ⁻⁴

510

511

Table 2 | SNPs with high selection frequency and important gene mapping results in 8 super-variants.

Super-variant	Chr	SNP name	position	Minor allele	Major allele	MAF	OR	p-value
chr2_197	2	rs73060484	196364477	C	A	0.069	1.945	6.0x10 ⁻⁴
		rs77578623	196369073	T	C	0.070	1.939	6.2x10 ⁻⁴
		rs74417002	196384505	G	A	0.034	1.832	3.0x10 ⁻²
		rs73070529	196412097	A	C	0.048	2.249	3.6x10 ⁻⁴
		rs113892140	196439005	A	G	0.044	2.031	2.8x10 ⁻³
		rs200008298	196602155	AATACT	A	0.032	1.8	3.1x10 ⁻²
		rs183712207	196611282	A	G	0.007	4.783	7.7x10 ⁻³
		rs191631470	196859045	T	C	0.007	3.335	3.9x10 ⁻²
		rs2176724	196952410	A	G	0.138	1.484	6.1x10 ⁻³
chr2_221	2	rs71040457	220294782	A	AG	0.355	1.331	7.7x10 ⁻³
chr6_148	6	rs117928001	147514999	T	C	0.049	2.749	1.1x10 ⁻⁵
		rs116898161	147538692	G	A	0.046	2.541	6.9x10 ⁻⁵
chr7_23	7	rs13227460	22588381	T	C	0.278	1.3	2.6x10 ⁻²
		rs55986907	22817292	T	C	0.286	1.601	3.5x10 ⁻⁵
chr8_99	8	rs7817272	98140470	C	T	0.194	1.736	1.7x10 ⁻⁵
		rs4735444	98140991	T	C	0.201	1.784	5.8x10 ⁻⁶

		rs1431889	98141643	C	G	0.193	1.704	3.5x10 ⁻⁵
		rs2874140	98142930	T	A	0.194	1.694	4.0x10 ⁻⁵
		rs531453964	98143128	CA	C	0.185	1.849	3.2x10 ⁻⁶
		rs7007951	98146644	T	C	0.184	1.711	4.4x10 ⁻⁵
		rs920576	98147539	C	T	0.201	1.615	1.6x10 ⁻⁴
chr10_57	10	rs9804218	56495374	G	C	0.357	1.373	3.3x10 ⁻³
chr16_4	16	rs2301762	3550977	G	C	0.055	2.541	2.0x10 ⁻⁵
chr17_26	17	rs60811869	25590833	C	T	0.024	2.966	6.5x10 ⁻⁴
		rs117217714	25987181	C	T	0.013	6.255	3.3x10 ⁻⁵

512


513

Table 3 Allelic distribution of contributing SNPs.			
rs4346407	0	1	2
Female	218	227	45
Male	236	255	80
10:56525802_CT_C	0	1	2
Female	76	21	9
Male	101	68	13

514


515

516



517


518 Figure 1: Survival curves of 8 identified super-variants in the complete dataset. The x-
519 axis represents days since testing, and the y-axis represents the survival probability.



520

521 Figure 2: Survival curves stratified by the number of super-variants in the complete
522 dataset. The x-axis represents days since testing, and the y-axis represents the survival
523 probability.

524



525

526 Figure 3: Manhattan plot of traditional single SNP association analysis based on samples

527 with white British ancestry only and controlled for gender and age. The red horizontal

528 line corresponds to the commonly adopted genome-wide significant level at 5×10^{-8} , and

529 the blue horizontal line gives to the suggestive significant level at 1×10^{-5} . Top SNPs

530 above the suggestive line in each chromosome are annotated.